Redx Pharma
Redx Pharma is a UK-based clinical-stage biopharmaceutical company developing small-molecule targeted therapies for oncology and fibrotic diseases, partnering with larger pharmaceutical firms to advance its pipeline, with lead candidate RXC008 in Crohn's disease.
- Company typePrivate
- Founded2010
- HeadquartersMacclesfield, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Redx Pharma does
Redx Pharma is a clinical-stage British biopharmaceutical company developing small-molecule targeted therapies for oncology and fibrotic diseases. Headquartered in Macclesfield, United Kingdom, with 51-100 employees and incorporated as Redx Pharma Ltd, the company is advancing a pipeline of precision medicines built around proprietary chemistry designed to deliver greater specificity and safety than existing therapeutic options. Its lead asset, RXC008 for fibrostenotic Crohn's disease, received FDA Fast Track Designation in March 2026 and is slated to enter Phase 2 trials later in the same year, supported by a research footprint that has historically spanned gastrointestinal, pulmonary fibrosis, and oncology indications.
The company's underlying technology is a medicinal-chemistry-led targeted medicine platform that has produced multiple internally-developed drug candidates, including the KRAS inhibitor program that was licensed and acquired by Jazz Pharmaceuticals in March 2025 to expand the acquirer's oncology pipeline. Redx Pharma's revenue model is asset-centric rather than product-centric: as a clinical-stage originator, it generates income primarily through one-time licensing transactions, milestone payments, and asset sales to larger pharmaceutical partners that possess the resources to fund late-stage clinical development and global commercialization, rather than through direct product sales. Its GTM motion is therefore partner-led, anchored on demonstrating clinical and regulatory milestones that validate its candidates for out-licensing or sale.
Customers of the company are other pharmaceutical firms (Jazz Pharmaceuticals being the named enterprise counterparty) rather than end patients or providers, with therapeutic indications and disease populations serving as downstream markets served through partners. Capital sources have historically included institutional equity investors — most notably a £35 million (~$43 million) placement in May 2022 — alongside grant funding (CARB-X), regional and EU growth capital, and historical LSE listing under ticker REDX.
Redx Pharma firmographics
Firmographics- Name
- Redx Pharma
- Legal name
- Redx Pharma Ltd
- Website
- https://redxpharma.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Redx Pharma is a UK-based clinical-stage biopharmaceutical company developing small-molecule targeted therapies for oncology and fibrotic diseases, partnering with larger pharmaceutical firms to advance its pipeline, with lead candidate RXC008 in Crohn's disease.
- Ownership category
- akta.pro rank
Redx Pharma industry classification
Industry- Product category
- Clinical-stage Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
- akta.pro secondary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where Redx Pharma is headquartered
LocationHeadquarters
- HQ city
- Macclesfield
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Redx Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Licensing and Asset Sales: Redx Pharma generates revenue through licensing agreements and asset sales to larger pharmaceutical companies. The company sold its KRAS inhibitor program to Jazz Pharmaceuticals and maintains a pipeline of targeted therapies in clinical development.
- Drug Development and Commercialization: As a clinical-stage biopharmaceutical company, Redx Pharma develops proprietary drug candidates through clinical trials with the aim of commercializing them upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Redx Pharma product offering
Product offeringCore offering
Redx Pharma is a clinical-stage biopharmaceutical company developing targeted precision medicines for oncology and fibrotic diseases. Its pipeline includes RXC008 for fibrostenotic Crohn's disease (FDA Fast Track Designation) and a KRAS inhibitor program for oncology, which was licensed to Jazz Pharmaceuticals. The company focuses on discovering and developing proprietary drug candidates designed to be more specific and safer than existing therapeutic options.
Product overview
Redx Pharma is a British targeted medicine company focused on developing precision drugs for oncology and fibrotic diseases. The company's pipeline includes RXC008 for fibrostenotic Crohn's disease and the KRAS inhibitor program for oncology applications.
Differentiator
Problem solved
Functional benefit
Products and services
- RXC008 A drug candidate being developed as a potential treatment for fibrostenotic Crohn's disease, designed to be more specific and safer than existing therapeutic options. Received FDA Fast Track Designation with planned Phase 2 trials.
- KRAS Inhibitor Program A targeted oncology drug development program for KRAS-mutated cancers. The program was acquired by Jazz Pharmaceuticals to expand their oncology pipeline and diversify their portfolio.
Quantifiable outcome
- FDA Fast Track Designation granted for RXC008 in fibrostenotic Crohn's disease
- +1 more outcomes
Companies that use Redx Pharma
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
Redx Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Redx Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Jazz PharmaceuticalsmajorJazz Pharmaceuticals acquired the KRAS inhibitor program from Redx Pharma as part of their strategy to expand their oncology pipeline and diversify their portfolio. This acquisition represents a significant licensing deal where Redx Pharma transferred rights to its KRAS inhibitor program to Jazz Pharmaceuticals.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Redx Pharma competitors and assessment
Company assessmentDirect peers
- Morphic Holding: Clinical-stage biotech developing oral integrin therapies for serious chronic diseases including inflammatory bowel disease. Closely comparable to Redx as a targeted small-molecule company with a GI-focused pipeline addressing fibrostenotic disease.
- Revolution Medicines: Clinical-stage precision oncology company developing targeted inhibitors including RAS(ON) inhibitors. Directly comparable to Redx as a precision-medicine oncology developer; the KRAS program was a key shared therapeutic area.
- Relay Therapeutics: Precision-medicine oncology company developing targeted therapies including KRAS G12C inhibitors. Comparable in approach and disease focus to Redx's pre-divestiture KRAS program.
- Pliant Therapeutics: Clinical-stage biotech developing therapeutics for fibrotic diseases, including in lung and GI indications. Directly comparable to Redx as a precision fibrosis drug developer targeting high-unmet-need fibrotic indications.
- Mirati Therapeutics: Targeted oncology company best known for KRAS G12C inhibitors; acquired by Bristol-Myers Squibb. Directly comparable therapeutic-area overlap with Redx's divested KRAS inhibitor program.
Broad incumbents
- Jazz Pharmaceuticals: Global specialty pharmaceutical company focused on neuroscience and oncology. Relevant as both a buyer (licensor of Redx's KRAS program) and a broader incumbent that validates the precision-oncology space Redx operates in.
- FibroGen: Biopharmaceutical company developing therapeutics for fibrotic diseases and anemia, with significant pulmonary fibrosis programs. Comparable as a larger fibrosis-focused peer operating in Redx's adjacent indications.
Regional players
- Hutchmed (Chi-Med): UK-listed, Asia-rooted precision oncology and immunology drug developer. Comparable as a clinical-stage targeted-medicine company with a similar listing profile and indication mix.
Emerging players
- Repare Therapeutics: Clinical-stage precision oncology company developing synthetic-lethal targeted therapies including against KRAS-mutant tumors. Comparable as a smaller, discovery-driven oncology peer with shared precision-medicine DNA.
- Black Diamond Therapeutics: Precision oncology company developing allosteric mutation-targeted therapies. Comparable as a small-cap, discovery-driven targeted-medicine company working in overlapping oncogenic driver space.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Redx Pharma social profiles
Digital presenceRedx Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Redx Pharma leadership team
Management profileNumber of profiles
Profiles4 records
Redx Pharma funding detail
Funding detailFunding overview
Funding rounds8 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Redx Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Redx Pharma
What does Redx Pharma do?
Redx Pharma is a clinical-stage biopharmaceutical company developing targeted precision medicines for oncology and fibrotic diseases. Its pipeline includes RXC008 for fibrostenotic Crohn's disease (FDA Fast Track Designation) and a KRAS inhibitor program for oncology, which was licensed to Jazz Pharmaceuticals. The company focuses on discovering and developing proprietary drug candidates designed to be more specific and safer than existing therapeutic options.
When was Redx Pharma founded?
Redx Pharma was founded in 2010. It employs 51 to 100 people.
Where is Redx Pharma based?
Redx Pharma is headquartered in Macclesfield, United Kingdom, in the Europe region.
How does Redx Pharma make money?
Two revenue lines are on record. Licensing and Asset Sales are the primary driver. The others are drug Development and Commercialization.
Who are Redx Pharma's main competitors?
Direct peers on record are Morphic Holding, Revolution Medicines, Relay Therapeutics, Pliant Therapeutics and Mirati Therapeutics. Broad incumbents are Jazz Pharmaceuticals and FibroGen. Hutchmed (Chi-Med) is listed as a regional player. Emerging players are Repare Therapeutics and Black Diamond Therapeutics.
Does Redx Pharma have an API?
No public API is recorded for Redx Pharma.
What industry is Redx Pharma in?
Redx Pharma's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.